Ideas

Combinatorial therapy for cancer: A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) increases the expression of mitochondrial protein LACTB, decreases levels of mitochondrial phosphatidylserine decarboxylase, alters mitochondrial lipid metabolism, and promotes differentiation of breast cancer cells via up-regulation of its target gene, 12/February/2018, 10.31 pm
Combinatorial therapy for cancer: A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) increases the expression of mitochondrial protein LACTB, decreases levels of mitochondrial phosphatidylserine decarboxylase, alters mitochondrial lipid metabolism, and promotes differentiation of breast cancer cells via up-regulation of its target gene, 12/February/2018, 10.31 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts, USA, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; and…

read more

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA HEIH  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/Februay/2019, 10.21 pm
Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA HEIH  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/Februay/2019, 10.21 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center for the Biology of…

read more

Natural product-derived Combination therapy for Squamous cell carcinoma of head and neck (HNSCC): A therapeutic mix encompassing  a therapeutic mix encompassing Metformin and Navitoclax/ABT-263   inhibits BMI1 and AP-1 expression, overcomes chemotherapeutic resistance, promotes chemosensitivity, suppresses cancer stem cells in HNSCC, and inhibits lymph node metastasis, via down-regulation of its target genes, 12/February/2017, 10.13 pm
Natural product-derived Combination therapy for Squamous cell carcinoma of head and neck (HNSCC): A therapeutic mix encompassing  a therapeutic mix encompassing Metformin and Navitoclax/ABT-263   inhibits BMI1 and AP-1 expression, overcomes chemotherapeutic resistance, promotes chemosensitivity, suppresses cancer stem cells in HNSCC, and inhibits lymph node metastasis, via down-regulation of its target genes, 12/February/2017, 10.13 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, Jonsson Comprehensive Cancer Center and Broad Stem Cell Research Center, UCLA, Los Angeles,…

read more

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA  ILF3-AS1  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/Februay/2019, 9.56 pm
Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA  ILF3-AS1  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/Februay/2019, 9.56 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center for the Biology of…

read more

Combinatorial therapy for Metastatic human tumors:  A pharmaceutical mixture encompassing metformin and Navitoclax/ABT-263 (MAN)  decreases the expression of c-Src protein, inhibits the expression of a number of enzymes in glycolytic cycle, and suppresses proliferation, migration, invasion, tumorigenesis and metastasis via upregulation of its target gene, 11/February/2017, 12.34 am
Combinatorial therapy for Metastatic human tumors:  A pharmaceutical mixture encompassing metformin and Navitoclax/ABT-263 (MAN)  decreases the expression of c-Src protein, inhibits the expression of a number of enzymes in glycolytic cycle, and suppresses proliferation, migration, invasion, tumorigenesis and metastasis via upregulation of its target gene, 11/February/2017, 12.34 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian 361102,…

read more

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA ATB increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 11/Februay/2019, 12.19 am
Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA ATB increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 11/Februay/2019, 12.19 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center for the Biology of…

read more
Start Typing